Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) shares were up 4.6% during trading on Monday. The stock traded as high as $45.09 and last traded at $45.2110. 1,649,732 shares changed hands during mid-day trading, an increase of 13% from the average daily volume of 1,460,310 shares. The stock had previously closed at $43.21.
Wall Street Analysts Forecast Growth
SRRK has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, October 15th. Truist Financial lifted their price target on Scholar Rock from $76.00 to $77.00 and gave the company a “buy” rating in a research note on Thursday, September 24th. Wedbush reissued an “outperform” rating and issued a $64.00 price target on shares of Scholar Rock in a research note on Tuesday, September 15th. Cantor Fitzgerald restated a “neutral” rating and issued a $70.00 price target on shares of Scholar Rock in a report on Monday, September 21st. Finally, UBS Group reaffirmed a “buy” rating on shares of Scholar Rock in a research report on Tuesday, September 15th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $67.67.
Check Out Our Latest Stock Analysis on SRRK
Scholar Rock Stock Up 3.1%
The company has a market capitalization of $5.43 billion, a P/E ratio of -13.26 and a beta of 0.78. The firm’s 50 day moving average price is $46.13 and its two-hundred day moving average price is $48.22. The company has a current ratio of 5.41, a quick ratio of 5.40 and a debt-to-equity ratio of 1.16.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.30 million. During the same quarter in the previous year, the company posted ($0.90) EPS. Equities research analysts forecast that Scholar Rock Holding Corporation will post -3.04 EPS for the current year.
Insider Transactions at Scholar Rock
In other Scholar Rock news, Director Srinivas Akkaraju purchased 146,970 shares of the business’s stock in a transaction on Monday, October 26th. The shares were purchased at an average cost of $41.59 per share, with a total value of $6,112,482.30. Following the transaction, the director directly owned 6,380,517 shares of the company’s stock, valued at $265,365,702.03. This represents a 2.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.30% of the company’s stock.
Institutional Trading of Scholar Rock
Hedge funds and other institutional investors have recently modified their holdings of the stock. Modern Wealth Management LLC grew its stake in Scholar Rock by 764.5% in the third quarter. Modern Wealth Management LLC now owns 52,075 shares of the company’s stock valued at $2,516,000 after purchasing an additional 46,051 shares in the last quarter. Integral Health Asset Management LLC increased its position in shares of Scholar Rock by 67.3% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,255,000 shares of the company’s stock worth $60,642,000 after purchasing an additional 505,000 shares during the last quarter. Cetera Investment Advisers bought a new stake in shares of Scholar Rock during the 3rd quarter worth approximately $2,392,000. Pathstone Holdings LLC raised its stake in shares of Scholar Rock by 16.6% during the 3rd quarter. Pathstone Holdings LLC now owns 33,560 shares of the company’s stock worth $1,622,000 after purchasing an additional 4,776 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Scholar Rock in the 3rd quarter valued at approximately $430,000. Institutional investors and hedge funds own 91.08% of the company’s stock.
Scholar Rock Company Profile
Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-?) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.
See Also
- Five stocks we like better than Scholar Rock
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
